Corbus to Begin Phase 3 Trial of Anabasum (Resunab) for Systemic Sclerosis Treatment. Corbus Pharmaceuticals, will commence a single Phase 3 clinical trial evaluating Anabasum (formerly known as Resunab or JBT-101) to treat diffuse cutaneous systemic sclerosis (SSc). The international, randomized, double–blind, placebo–controlled trial will enroll about 270 adults with SSc. Scleroderma News, 04/06/2017. (Also see Clinical Trials)
Lung Transplantation in Patients With Systemic Sclerosis. Multiple recent reports provide convincing findings that scleroderma patients undergoing lung transplantation have similar outcomes as those with other non–rheumatologic pulmonary conditions, even when significant esophageal dysmotility is present. PubMed, Curr Rheumatol Rep, 2017 May;19(5):23. (Also see Lung Transplants)
Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis (LcSSc). We found no association between the patterns of capillaroscopy and SSc subtypes; early scleroderma pattern of capillaroscopy was significantly associated with early LcSSc, compatible with the slower course of the disease in LcSSc. PubMed, Reumatologia, 2017;55(1):15-23. (Also see Nailfold Capillaroscopy)
Fatigue in patients with systemic sclerosis (SSc) and hypothyroidism. A review of the literature and report of our experience. The results suggest that female SSc patients could be screened for thyroid function, overall in presence of fatigue symptoms, and that an appropriate L-thyroxine substitutive therapy could be useful to mitigate these symptoms. PubMed, Clin Exp Rheumatol, 04/04/2017. (Also see Fatigue and Thyroid Diseases)
CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis (SSc). These results suggest that CD16+ monocytes are associated with the main fibrotic manifestations of SSc and their role in the pathogenesis of fibrosis in this autoimmune disorder should therefore be further considered. PubMed, Clin Rheumatol, 03/14/2017. (Also see Skin Fibrosis)
Serum levels of genomic DNA of α1(I) collagen are elevated in scleroderma patients. In summary, elevation of serum α1(I) collagen DNA levels in scleroderma patients may be useful as the diagnostic marker, reflecting the presence of vasculopathy. PubMed, J Dermatol, 03/31/2017. (Also see Vascular Involvement)
Long-term efficacy and tolerability of mycophenolate mofetil (MMF) therapy in diffuse scleroderma (dcSSc) skin disease. MMF was associated with a modest improvement in modified Rodnan skin score (mRSS) and was well tolerated in the treatment of dcSSc. PubMed, Int J Rheum Dis, 03/24/2017. (Also see Immunosuppressants)
Review article: pathogenesis and clinical manifestations of gastrointestinal involvement (GI) in systemic sclerosis (SSc). The pathogenesis of GI in SSc remains elusive and an improved understanding of novel pathogenic mechanisms may allow the development of potentially highly effective approaches, including intravenous immunoglobulin and microRNA based therapeutic interventions. PubMed, Aliment Pharmacol Ther, 2017 Apr;45(7):883-898. (Also see Gastrointestinal Involvement)
Readdressing the entity of exercise pulmonary arterial hypertension (EPAH). Patients with collagen vascular disease, especially scleroderma, are at risk for EPAH and its presence indicates a relatively poor prognosis. PubMed, Respir Med, 2017 Mar;124:65-71. (Also see Pulmonary Hypertension)
Clinical Algorithms for the Diagnosis and Prognosis of Interstitial Lung Disease (ILD) in Systemic Sclerosis (SSc). Clinical algorithms had a good diagnostic performance for extents of SSc–ILD on high–resolution computed tomography (HRCT) with clinical and prognostic relevance (≥10 and ≥20%), and were also strongly related to mortality. Seminars in Arthritis and Rheumatism, 03/31/2017. (Also see Severity and Prognosis for Scleroderma Pulmonary Involvement)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: